Boston Scientific Weighs Endosurgery IPO, Other Asset Sales To Repay Debt
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is evaluating the potential sale of a minority equity stake in its endosurgery group and may consider additional asset sales to help accelerate repayment of debt incurred in its purchase of Guidant nearly a year ago, the company says